Cellular Alterations in Immune Checkpoint Inhibitor Therapy-Related Cardiac Dysfunction.

IF 3.8 Q1 CARDIAC & CARDIOVASCULAR SYSTEMS Current Heart Failure Reports Pub Date : 2024-06-01 Epub Date: 2024-03-02 DOI:10.1007/s11897-024-00652-2

Lars Michel, Peter Ferdinandy, Tienush Rassaf

{"title":"Cellular Alterations in Immune Checkpoint Inhibitor Therapy-Related Cardiac Dysfunction.","authors":"Lars Michel, Peter Ferdinandy, Tienush Rassaf","doi":"10.1007/s11897-024-00652-2","DOIUrl":null,"url":null,"abstract":"Purpose of review: Immune checkpoint inhibitor (ICI) therapy has emerged as a pivotal advancement in cancer treatment, but the widespread adoption has given rise to a growing number of reports detailing significant cardiovascular toxicity. This review concentrates on elucidating the mechanisms behind ICI-related cardiovascular complications, emphasizing preclinical and mechanistic data.Recent findings: Accumulating evidence indicates a more significant role of immune checkpoints in maintaining cardiac integrity than previously understood, and new key scientific data are available to improve our understanding of ICI-related cardiovascular toxicity, including hidden cardiotoxicity. New avenues for innovative concepts are hypothesized, and opportunities to leverage the knowledge from ICI-therapy for pioneering approaches in related scientific domains can be derived from the latest scientific projects. Cardiotoxicity from ICI therapy is a paramount challenge for cardio-oncology. Understanding the underlying effects builds the foundation for tailored cardioprotective approaches in the growing collective at risk for severe cardiovascular complications.","PeriodicalId":10830,"journal":{"name":"Current Heart Failure Reports","volume":" ","pages":"214-223"},"PeriodicalIF":3.8000,"publicationDate":"2024-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11090976/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Current Heart Failure Reports","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1007/s11897-024-00652-2","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/3/2 0:00:00","PubModel":"Epub","JCR":"Q1","JCRName":"CARDIAC & CARDIOVASCULAR SYSTEMS","Score":null,"Total":0}

引用次数: 0

Abstract

Purpose of review: Immune checkpoint inhibitor (ICI) therapy has emerged as a pivotal advancement in cancer treatment, but the widespread adoption has given rise to a growing number of reports detailing significant cardiovascular toxicity. This review concentrates on elucidating the mechanisms behind ICI-related cardiovascular complications, emphasizing preclinical and mechanistic data.

Recent findings: Accumulating evidence indicates a more significant role of immune checkpoints in maintaining cardiac integrity than previously understood, and new key scientific data are available to improve our understanding of ICI-related cardiovascular toxicity, including hidden cardiotoxicity. New avenues for innovative concepts are hypothesized, and opportunities to leverage the knowledge from ICI-therapy for pioneering approaches in related scientific domains can be derived from the latest scientific projects. Cardiotoxicity from ICI therapy is a paramount challenge for cardio-oncology. Understanding the underlying effects builds the foundation for tailored cardioprotective approaches in the growing collective at risk for severe cardiovascular complications.

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

免疫检查点抑制剂疗法导致的心功能障碍中的细胞变化

综述目的：免疫检查点抑制剂（ICI）疗法已成为癌症治疗领域的一项重要进展，但其广泛应用也引发了越来越多关于心血管毒性的报道。这篇综述集中阐明了 ICI 相关心血管并发症背后的机制，强调了临床前和机理数据：不断积累的证据表明，免疫检查点在维持心脏完整性方面的作用比以前所理解的更为重要，而且新的关键科学数据的出现提高了我们对 ICI 相关心血管毒性（包括隐性心脏毒性）的认识。最新的科学项目提出了创新概念的新途径，并提供了在相关科学领域利用 ICI 治疗知识开创性方法的机会。ICI 疗法引起的心脏毒性是心脏肿瘤学面临的最大挑战。了解其潜在影响可为针对越来越多的严重心血管并发症高危人群量身定制心脏保护方法奠定基础。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文去求助

来源期刊

Current Heart Failure Reports Medicine-Emergency Medicine

CiteScore

5.30

自引率

0.00%

发文量

期刊介绍： This journal intends to provide clear, insightful, balanced contributions by international experts that review the most important, recently published clinical findings related to the diagnosis, treatment, management, and prevention of heart failure. We accomplish this aim by appointing international authorities to serve as Section Editors in key subject areas, such as investigative, pharmacologic, and nonpharmacologic therapies, pathophysiology, and prevention. Section Editors, in turn, select topics for which leading experts contribute comprehensive review articles that emphasize new developments and recently published papers of major importance, highlighted by annotated reference lists. An international Editorial Board reviews the annual table of contents, suggests articles of special interest to their country/region, and ensures that topics are current and include emerging research. Commentaries from well-known figures in the field are also provided.

期刊最新文献

Cardiogenic Shock: Focus on Non-Cardiac Biomarkers. Biomarkers of Hemodynamic Congestion in Heart Failure. Heart Failure in Rheumatoid Arthritis: Clinical Implications. Screening for Heart Failure: Biomarkers to Detect Heightened Risk in the General Population. Troponin Elevation in Asymptomatic Cancer Patients: Unveiling Connections and Clinical Implications.